What is Mogrify?
Mogrify is a biopharmaceutical innovator dedicated to transforming the landscape of regenerative medicine. The company specializes in the development of ex vivo cell therapies and is at the forefront of pioneering in vivo reprogramming therapies. By utilizing a systematic, data-driven approach to identify the specific transcription factors required to convert one cell type into another, Mogrify is effectively unlocking new possibilities for treating complex diseases.
The firm's market position is defined by its ability to bridge the gap between fundamental biological research and scalable therapeutic manufacturing. As the industry shifts toward more personalized and precise interventions, Mogrify's platform serves as a foundational technology, enabling the rapid discovery and development of novel cell-based treatments that were previously considered unattainable.
How much funding has Mogrify raised?
Mogrify has raised a total of $47.8M across 4 funding rounds:
Angel/Seed
$3.7M
Private Equity
$1.1M
Series A
$33M
Series A
$10M
Angel/Seed (2019): $3.7M with participation from Dr Disley, 24Haymarket, and Ahren
Private Equity (2020): $1.1M led by SBRI Healthcare
Series A (2021): $33M supported by Dr. Jonathan Milner, Parkwalk Advisors, University of Bristol Enterprise Fund III, Ahren Innovation Capital, Astellas Venture Management, Dr. Darrin Disley, and 24Haymarket
Series A (2023): $10M featuring Ahren Innovation Capital, Parkwalk Advisors, and Astellas Venture Management
Key Investors in Mogrify
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive.
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science, providing both patient and active capital to empower visionary entrepreneurs.
24Haymarket
24Haymarket Limited is a private network of experienced investors and operators focused on capital investment, partnering with exceptional entrepreneurs to provide funding and support for their ventures.
What's next for Mogrify?
With the recent influx of $10M, Mogrify is well-positioned to scale its operational capabilities and accelerate its clinical development programs. The strategic focus will likely center on expanding its internal therapeutic pipeline while continuing to refine its proprietary reprogramming engine. As the company transitions into more advanced stages of clinical validation, the emphasis will shift toward establishing key partnerships and optimizing manufacturing processes to ensure the commercial viability of its therapeutic candidates.
Investors remain focused on the company's ability to translate its scientific breakthroughs into tangible patient outcomes. Given the current funding context, Mogrify is expected to leverage its deep science expertise to maintain its competitive edge in the rapidly evolving biotech landscape, potentially setting the stage for future licensing agreements or strategic collaborations with global pharmaceutical leaders.
